Evidence map›Paper›PMID 37049243›Full record

ArticleNanomaterials (Basel, Switzerland)2023

Xenogenic Implantation of Human Mesenchymal Stromal Cells Using a Novel 3D-Printed Scaffold of PLGA and Graphene Leads to a Significant Increase in Bone Mineralization in a Rat Segmental Femoral Bone Defect.

Steven D Newby, Chris Forsynth, Austin J Bow, Shawn E Bourdo, Man Hung, Joseph Cheever, Ryan Moffat, Andrew J Gross, Frank W Licari, Madhu S Dhar

Open access · goldAbstract read
In one paragraph

Article in Nanomaterials (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Steven D NewbyLarge Animal Regenerative Medicine Program, Department of Large Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, TN 37996, USA.
Chris ForsynthDepartment of Biomedical Engineering, University of Tennessee, Knoxville, TN 37996, USA.
Austin J BowLarge Animal Regenerative Medicine Program, Department of Large Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, TN 37996, USA.ORCID 0000-0003-1975-7364
Shawn E BourdoCenter for Integrative Nanotechnologies, University of Arkansas at Little Rock, Little Rock, AR 72204, USA.
Man HungCollege of Dental Medicine, Roseman University of Health Sciences, 10894 S River Front Parkway, South Jordan, UT 84095, USA.ORCID 0000-0003-2827-3740
Joseph CheeverCollege of Dental Medicine, Roseman University of Health Sciences, 10894 S River Front Parkway, South Jordan, UT 84095, USA.
Ryan MoffatCollege of Dental Medicine, Roseman University of Health Sciences, 10894 S River Front Parkway, South Jordan, UT 84095, USA.
Andrew J GrossCollege of Dental Medicine, Roseman University of Health Sciences, 10894 S River Front Parkway, South Jordan, UT 84095, USA.
Frank W LicariCollege of Dental Medicine, Roseman University of Health Sciences, 10894 S River Front Parkway, South Jordan, UT 84095, USA.
Madhu S DharLarge Animal Regenerative Medicine Program, Department of Large Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, TN 37996, USA.ORCID 0000-0002-0610-5351
Roseman University of Health Sciences · USUniversity of Tennessee at Knoxville · USUniversity of Arkansas at Little Rock · US

Funding

National Institute of Health R15AR070460
6 · The paper itself

Abstract

Tissue-engineering technologies have the potential to provide an effective approach to bone regeneration. Based on the published literature and data from our laboratory, two biomaterial inks containing PLGA and blended with graphene nanoparticles were fabricated. The biomaterial inks consisted of two forms of commercially available PLGA with varying ratios of LA:GA (65:35 and 75:25) and molecular weights of 30,000-107,000. Each of these forms of PLGA was blended with a form containing a 50:50 ratio of LA:GA, resulting in ratios of 50:65 and 50:75, which were subsequently mixed with a 0.05 wt% low-oxygen-functionalized derivative of graphene. Scanning electron microscopy showed interconnected pores in the lattice structures of each scaffold. The cytocompatibility of human ADMSCs transduced with a red fluorescent protein (RFP) was evaluated in vitro. The in vivo biocompatibility and the potential to repair bones were evaluated in a critically sized 5 mm mechanical load-bearing segmental femur defect model in rats. Bone repair was monitored by radiological, histological, and microcomputed tomography methods. The results showed that all of the constructs were biocompatible and did not exhibit any adverse effects. The constructs containing PLGA (50:75)/graphene alone and with hADMSCs demonstrated a significant increase in mineralized tissues within 60 days post-treatment. The percentage of bone volume to total volume from microCT analyses in the rats treated with the PLGA + cells construct showed a 50% new tissue formation, which matched that of a phantom. The microCT results were supported by Von Kossa staining.

Indexed as

3D bioprintingadditive manufacturingPLGA blendspoly(lactic-co-glycolic acid)rat femur

Identifiers

PMID37049243
PMCPMC10097331
OpenAlexW4360859104

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.